Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMercia Asset Regulatory News (MERC)

Share Price Information for Mercia Asset (MERC)

Share Price is delayed by 15 minutes
Get Live Data
28.75    0.00 (0.00%)
Bid:
28.50
Ask:
29.00
Spread: 0.50 (1.754%)
Market Cap: £121.72m
MERC Live PriceLast checked at - London Stock Exchange

Intraday Mercia Asset Share Chart

Share Buyback Programme

1 Apr 2026 07:00

RNS Number : 9306Y
Mercia Asset Management PLC
01 April 2026
 

RNS 1 April 2026

 

Mercia Asset Management PLC

 

("Mercia", the "Company" or the "Group")

 

Share Buyback Programme

 

Mercia Asset Management PLC (AIM: MERC), the regionally focused, private capital asset manager with over £2.0billion of assets under management, today announces that it is commencing a new share buyback programme of up to £3.0million (the "Share Buyback Programme"), in line with its annual share buyback policy. Shares bought back will be cancelled.

 

The Share Buyback Programme will be for on market purchases of up to £3.0million of Ordinary shares in the Company (the "Maximum Monetary Amount"), in accordance with certain pre-set parameters (the "Share Buyback").

 

Mercia has entered into arrangements with Canaccord Genuity Limited ("Canaccord Genuity") (the "Broker") to conduct this new Share Buyback Programme on its behalf on a broker-managed basis, in relation to the purchase of Ordinary shares of Mercia (the "Ordinary Shares").

 

The Broker will make trading decisions in relation to Shares purchased under the Share Buyback Programme independently of, and uninfluenced by, Mercia.

 

 

Further details of the Share Buyback Programme

 

· The purpose of the Share Buyback Programme is to reduce the share capital of the Company and to return capital to those shareholders wishing to participate in the Share Buyback.

 

· The Share Buyback will be financed from existing cash resources.

 

· The Share Buyback will take place within the limitations of the authority granted to the Board of Mercia to repurchase Ordinary shares granted by its shareholders from time to time (at the Company's Annual General Meeting, held on 25 September 2025, shareholders gave the Company authority to purchase a maximum of 43,244,112 Ordinary shares (the "General Authority").

 

· In accordance with the General Authority, the maximum price paid per Ordinary Share acquired by the Company pursuant to the Share Buyback is to be no more than the higher of: (i) 5% above the average of the mid-market value of the Ordinary Shares for the five business days before the purchase is made; and (ii) the higher of the last independent trade and the highest current independent bid, for any number of Ordinary Shares on the trading venue where the purchase is carried out. Furthermore, in accordance with the General Authority the minimum price payable per Ordinary Share acquired by the Company pursuant to the Share Buyback is 0.001 pence.

 

· It is intended that the Share Buyback Programme will be conducted within the volume limits of the exemption contained in Article 5(1) of the Regulation. However, given the relatively limited liquidity in the Shares, the Company has agreed that, on any trading day, a buy-back of Ordinary Shares under the Share Buyback Programme may exceed 25 per cent. but remain below 50 per cent. of the average daily trading volume in the Shares in the 20 trading days preceding the date on which a buy-back of Ordinary Shares is carried out. Accordingly, the Company may not benefit from the exemption contained in the Market Abuse Regulation (EU 596/2014) with respect to such trading dates.

 

· The Share Buyback will commence on the date of this announcement and will continue until the earlier of (i) 31 March 2027; (ii) the point at which the total monetary value of Ordinary Shares purchased under the Share Buyback reaches the Maximum Monetary Amount or (iii) the process is terminated or paused.

 

· The purchased Ordinary Shares will be cancelled.

 

· Share buybacks will take place in open market transactions and may be made from time to time depending on market conditions, share price and trading volume. There is no certainty that any buybacks will be completed. The Share Buyback may be paused at any time if deemed appropriate by the Brokers with respect to market conditions.

 

· Mercia intends to announce any purchase of Ordinary Shares under the Share Buyback Programme on a weekly basis, and in any event by no later than the end of the seventh daily market session following the date of execution.

 

The Board has determined that the continuation of its share buyback policy remains in the best interests of the Company and its shareholders.

 

 

Ends

 

For further information, please contact:

 

Mercia Asset Management PLC

Mark Payton, Chief Executive Officer

Martin Glanfield, Chief Financial Officer

www.mercia.co.uk +44 (0)330 223 1430

 

Canaccord Genuity Limited (NOMAD and Joint Broker)

Simon Bridges, Emma Gabriel, Harry Rees +44 (0)20 7523 8000

 

Singer Capital Markets (Joint Broker)

Charles Leigh-Pemberton +44 (0)20 7496 3000

 

FTI Consulting

Tom Blackwell, Thomas Lodge +44 (0)20 3727 1051

mercia@fticonsulting.com

 

About Mercia Asset Management PLC

Mercia is a private capital asset manager focused on supporting regional SMEs to achieve their growth aspirations. Mercia provides capital across its four asset classes of venture, development capital, property finance and proprietary capital: the Group's 'Complete Connected Capital'.

 

The Group has a strong UK footprint through its 11 regional offices, extensive local adviser and personal networks, and university partnerships, providing it with access to high-quality deal flow.

 

Mercia Asset Management PLC is quoted on AIM with the EPIC "MERC".

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSDAFMFEMSEDD
Date   Source Headline
3rd Sep 20217:00 amRNSInvestment into Locate Bio
10th Aug 20217:00 amRNSMercia accredited to deliver Recovery Loan Scheme
4th Aug 20217:00 amRNSnDreams appoints new Non-executive Chair
30th Jul 20217:00 amRNSPublication of Annual Report and Notice of AGM
15th Jul 20217:00 amRNSNotification of Major Holdings
12th Jul 20217:00 amRNSGrant of Options
8th Jul 20212:56 pmRNSDirector/PDMR Dealings
6th Jul 20217:00 amRNSPreliminary results
24th Jun 20217:00 amRNSInvestor Presentation
23rd Jun 20213:16 pmRNSPerformance fee entitlement and trading update
10th May 20217:00 amRNSPublication of "The Insight" Newsletter
15th Apr 20217:00 amRNSNotice of Results
12th Apr 20217:00 amRNSVirtual shareholder event
6th Apr 20212:37 pmRNSMyHealthChecked plc signs major contract
5th Mar 202112:46 pmRNSNotification of Major Holdings
4th Mar 20214:09 pmRNSDirector/PDMR Dealings
3rd Mar 20217:00 amEQSEdison Investment Research Limited: Mercia Asset Management (MERC): The UK's top regional investor
1st Mar 20213:31 pmRNSTrading Update
1st Mar 20213:27 pmRNSSale of Oxford Genetics Limited
23rd Feb 20217:00 amRNSSoccer Manager receives £3.0million investment
2nd Feb 20217:00 amRNSSoftware and eCommerce portfolio update
29th Jan 20217:00 amRNSChange of Auditor
8th Dec 20207:00 amRNSQuarterly newsletter
2nd Dec 20207:00 amRNSPerformance fee entitlement
1st Dec 20207:00 amRNSInterim Results
27th Nov 20207:00 amRNSInvestor Presentation
6th Nov 20207:00 amRNSNotice of Results and Investor Presentations
3rd Nov 20207:00 amRNSBoard Appointment
30th Oct 20207:30 amRNSNew direct investment into Sense Biodetection
19th Oct 20207:00 amRNSSuccessful exit of Clear Review
7th Oct 20207:00 amRNSWarwick Acoustics Update
25th Sep 20207:00 amRNSDirector/PDMR Dealings
24th Sep 202010:29 amRNSResult of AGM
24th Sep 20207:00 amRNSAGM Statement
18th Sep 20207:00 amRNSLife Sciences’ Portfolio Update
24th Aug 20207:00 amRNSGrant of Options
31st Jul 20207:03 amRNSPublication of Annual Report
29th Jul 20202:31 pmRNSDirector/PDMR Dealings
14th Jul 20207:00 amRNSPreliminary results
9th Jul 20207:00 amRNSSale of The Native Antigen Company
1st Jul 20207:00 amRNSPortfolio company MIP Diagnostics raises £5.1m
11th Jun 20207:00 amRNSNotice of Results
27th May 202011:08 amRNSMercia accredited by BBB under CBILS
14th May 20207:00 amRNSMedherant partners with Cycle Pharmaceuticals
6th May 20207:00 amRNSInvestment into OXGENE
21st Apr 20207:00 amRNSBritish Business Bank increases Mercia’s mandate
3rd Apr 202012:47 pmRNSNVM VCTs raise £38.2 million
2nd Apr 20207:00 amRNSPortfolio companies collaborate against COVID-19
27th Mar 202011:30 amRNSDirector/PDMR Dealings
25th Mar 20203:08 pmRNSCOVID-19 Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.